Novo Nordisk partners with GoodRx for $499 monthly Ozempic, Wegovy (GDRX:NASDAQ)

has entered into a collaboration with GoodRx (NASDAQ:GDRX) to supply type 2 diabetes and weight loss meds Ozempic and Wegovy for $499 a month for self-pay customers. GoodRx has surged ~29% in early morning trading Monday.